A new light brings a new hope
Eclipse is the first and the Only head-to-head double-blind
phase three clinical trial of Tremfya IL 23 inhibitor
compared with Secukinumab1 (IL-17 inhibitor)
in patients with moderate to severe plaque psoriasis2.
TODAY we are sharing the study results
in a less than 3 minutes video
For Adverse Events or safety related issues, please approach group mailbox PVNEMA@ITS.JNJ.COM.
For Product Quality Complaints and temperature Excursions, please approach group mailbox QANEMA@ITS.JNJ.COM
Janssen Lebanon branch +961 1 518700
1. Reich et al. Lancet 2019;394:831-9.
2. Tremfya EU SmPC, Feb 2019